Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002135161 | SCV002447213 | likely benign | not provided | 2024-02-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003061768 | SCV003541194 | uncertain significance | Inborn genetic diseases | 2020-10-21 | criteria provided, single submitter | clinical testing | The c.8806C>A (p.Q2936K) alteration is located in exon 9 (coding exon 9) of the FAT4 gene. This alteration results from a C to A substitution at nucleotide position 8806, causing the glutamine (Q) at amino acid position 2936 to be replaced by a lysine (K). Based on data from the Genome Aggregation Database (gnomAD) database, the FAT4 c.8806C>A alteration was observed in 0.01% (21/281458) of total alleles studied, with a frequency of 0.08% (20/24890) in the African subpopulation. This amino acid position is well conserved in available vertebrate species. The p.Q2936K alteration is predicted to be tolerated by in silico analysis. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005032176 | SCV005659983 | uncertain significance | Van Maldergem syndrome 2; Hennekam lymphangiectasia-lymphedema syndrome 2 | 2024-05-10 | criteria provided, single submitter | clinical testing |